WO2008049657A3 - Use of (meth)acrylate copolymers in slow-release pharmaceutical forms for reducing the influence of ethanol on active ingredient release - Google Patents

Use of (meth)acrylate copolymers in slow-release pharmaceutical forms for reducing the influence of ethanol on active ingredient release Download PDF

Info

Publication number
WO2008049657A3
WO2008049657A3 PCT/EP2007/058100 EP2007058100W WO2008049657A3 WO 2008049657 A3 WO2008049657 A3 WO 2008049657A3 EP 2007058100 W EP2007058100 W EP 2007058100W WO 2008049657 A3 WO2008049657 A3 WO 2008049657A3
Authority
WO
WIPO (PCT)
Prior art keywords
release
active ingredient
meth
influence
acrylate copolymers
Prior art date
Application number
PCT/EP2007/058100
Other languages
German (de)
French (fr)
Other versions
WO2008049657A2 (en
Inventor
Hans-Ulrich Petereit
Brigitte Skalsky
Diego Gallardo
Manfred Assmus
Andreas Gryczke
Wolfgang Weisbrod
Felix Hofmann
Hans Baer
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of WO2008049657A2 publication Critical patent/WO2008049657A2/en
Publication of WO2008049657A3 publication Critical patent/WO2008049657A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the use of (meth)acrylate copolymers which are insoluble in gastric juice in oral slow-release pharmaceutical forms to form a matrix for the contained active ingredient to reduce the effect of increasing or decreasing the rate of active ingredient release through the influence of ethanol under in vitro conditions.
PCT/EP2007/058100 2006-10-26 2007-08-06 Use of (meth)acrylate copolymers in slow-release pharmaceutical forms for reducing the influence of ethanol on active ingredient release WO2008049657A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200610051020 DE102006051020A1 (en) 2006-10-26 2006-10-26 Use of enteric (meth)acrylate copolymers in controlled-release oral pharmaceutical dosage forms as drug matrix formers to reduce the effect of ethanol-induced release rate increase or decrease in vitro
DE102006051020.8 2006-10-26

Publications (2)

Publication Number Publication Date
WO2008049657A2 WO2008049657A2 (en) 2008-05-02
WO2008049657A3 true WO2008049657A3 (en) 2008-10-30

Family

ID=38521102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/058100 WO2008049657A2 (en) 2006-10-26 2007-08-06 Use of (meth)acrylate copolymers in slow-release pharmaceutical forms for reducing the influence of ethanol on active ingredient release

Country Status (3)

Country Link
DE (1) DE102006051020A1 (en)
TW (1) TW200833372A (en)
WO (1) WO2008049657A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2696341C (en) 2007-08-13 2016-05-17 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
PL2326313T3 (en) 2008-09-24 2015-08-31 Evonik Roehm Gmbh Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
CN104984343B (en) * 2008-09-24 2019-04-02 赢创罗姆有限公司 The pharmaceutical composition of the dependent controlled release of pH for the non-opium drug that ethanol tolerant influences
US9757343B2 (en) * 2008-09-24 2017-09-12 Evonik Röhm Gmbh PH-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
BRPI0924427A2 (en) * 2009-03-18 2016-01-26 Evonik Roehm Gmbh controlled release pharmaceutical composition, its preparation process and its use
CN105287434A (en) * 2009-03-18 2016-02-03 赢创罗姆有限公司 Ethanol influence-resistant controlled-release medicine composition adopting coating containing neutral vinyl polymers and excipients
MX2011009667A (en) 2009-03-18 2011-12-14 Evonik Roehm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients.
KR101479388B1 (en) 2010-05-10 2015-01-05 유로-셀티큐 에스.에이. Combination of active loaded granules with additional actives
MX340188B (en) * 2010-05-10 2016-06-30 Euro-Celtique S A * Manufacturing of active-free granules and tablets comprising the same.
CH705273B1 (en) 2010-05-10 2016-06-15 Euro Celtique Sa Pharmaceutical composition - comprising hydromorphone and naloxone.
BR112013032095A8 (en) 2011-06-17 2022-07-05 Evonik Roehm Gmbh COATING COMPOSITION SUITABLE FOR PHARMACEUTICAL OR NUTRACEUTICAL DOSAGE FORMS
RU2649806C2 (en) 2011-06-17 2018-04-04 Эвоник Рем ГмбХ Gastral-resistant pharmaceutical or nutraceutical composition with sustainability to the ethanol impact
CA2839494C (en) 2011-06-17 2018-11-06 Evonik Roehm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
US20140275150A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
SG11201602884WA (en) 2013-11-13 2016-05-30 Euro Celtique Sa Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
WO2020182596A1 (en) 2019-03-11 2020-09-17 Evonik Operations Gmbh Dosage form comprising a polymeric matrix

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074033A1 (en) * 2002-02-11 2003-09-12 Pliva-Istrazivacki Institut D.O.O. Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
WO2006079550A2 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
WO2006094083A1 (en) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
WO2007053698A2 (en) * 2005-10-31 2007-05-10 Alza Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
WO2007085024A2 (en) * 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
WO2008011595A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152414A (en) * 1978-08-18 1979-05-01 Iowa State University Research Foundation, Inc. Combination vaccine for swine dysentery and method of use
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
EP1301177A2 (en) * 2000-07-10 2003-04-16 Therics, Inc. Method and materials for controlling migration of binder liquid in a powder
DE10058771A1 (en) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Coacervation process for the production of delayed-release drugs
PL1765303T5 (en) * 2004-07-01 2023-05-22 Grünenthal GmbH Oral dosage form safeguarded against abuse

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074033A1 (en) * 2002-02-11 2003-09-12 Pliva-Istrazivacki Institut D.O.O. Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
WO2006079550A2 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
WO2006094083A1 (en) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
WO2007053698A2 (en) * 2005-10-31 2007-05-10 Alza Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
WO2007085024A2 (en) * 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
WO2008011595A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system

Also Published As

Publication number Publication date
WO2008049657A2 (en) 2008-05-02
TW200833372A (en) 2008-08-16
DE102006051020A1 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
WO2008049657A3 (en) Use of (meth)acrylate copolymers in slow-release pharmaceutical forms for reducing the influence of ethanol on active ingredient release
WO2010066749A3 (en) Ulipristal acetate tablets
WO2006084164A3 (en) Gastric retention and controlled release delivery system
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
PL1906939T3 (en) Use of a partially neutralized, anionic (meth)acrylate copolymer as a coating for the production of a medicament releasing active substance at reduced ph values
WO2009117130A3 (en) Extended release forumulation containing a wax
WO2009063222A3 (en) Solid compositions
IL192773A0 (en) Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol
WO2008061226A3 (en) Sustained-release formulations of topiramate
EP3272337A3 (en) Tablets
EP2045251A4 (en) Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses
WO2008052033A3 (en) Ibuprofen composition
WO2009051022A3 (en) Matrix-type pharmaceutical solid preparation
MY144857A (en) Phamaceutical composition comprising amlodipine and losartan
WO2011101866A3 (en) Gastric retention formulation containing baclofen
WO2011053003A3 (en) Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer
JO2973B1 (en) Fumarate Salt Of (alphaS, betaR)-6-Bromo-alfa-[2-(dimethylamino)ethyl]-2- Methoxy-alpha-1-naphthalenyl-beta-phenyl-3- Quinolineethanol
WO2007016284A3 (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2008113901A3 (en) Composition with controlled release of levetiracetam and method for preparing same
EP2153834A3 (en) Extended release pharmaceutical compositions comprising quetiapine salts
WO2008005353A3 (en) Immediate-release tablet formulations of a thrombin receptor antagonist
WO2009068708A3 (en) Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07802495

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07802495

Country of ref document: EP

Kind code of ref document: A2